Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.
NexImmune, a US-based cancer immunotherapy developer based on Johns Hopkins University reserach, filed for an $86.3m initial public offering on the Nasdaq Global Market on Tuesday that would give pharmaceutical firms Pfizer and Amgen the chance to exit.
NexImmune is working on immunotherapies based on a nanotechnology platform that are intended to leverage nanoparticles that function as synthetic dendritic cells in order to locate and activate natural T cells to fight off cancer cells.
The IPO proceeds…
